Market Closed - Xetra 12:36:00 2024-03-28 pm EDT 5-day change 1st Jan Change
46.35 EUR 0.00% Intraday chart for Formycon AG +0.32% -17.82%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar MT
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative DJ
Formycon Wins Regulatory Nod for Lucentis Biosimilar in Saudi Arabia MT
Formycon Sells 9% Interest to Gedeon Richter for EUR83 Million MT
EU Medicines Regulator Accepts Formycon's Marketing Authorization Application for Eylea Biosimilar MT
Formycon JV Wins Canadian Approval for Retinal Diseases Treatment Ranopto MT
Formycon AG, Polpharma Biologics Group BV, Bioeq AG and Teva Canada Ltd. Announces Health Canada Approves FYB201/Ranopto (Ranibizumab) CI
US FDA Accepts for Review Formycon, Fresenius' Biologics License Application for Stelara Biosimilar MT
Novartis AG : Sandoz takes its first steps on the stock exchange Our Logo
EU Medicines Regulator Accepts Marketing Authorization Application for Formycon's Biosimilar Candidate MT
Formycon AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI
US FDA Accepts Formycon's Biologics License Application for Eylea Biosimilar MT
Formycon, Fresenius to Launch Biosimilar for Johnson & Johnson's Anti-inflammatory Drug by 2025 MT
Certain Shares of Formycon AG are subject to a Lock-Up Agreement Ending on 2-AUG-2023. CI
Formycon Announces Submission of the Biologics License Application for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration CI
Jefferies starts Formycon with 'Buy' - Target 101 euros DP
Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Formycon AG Provides Earnings Guidance for the Year 2023 CI
Formycon Concludes Clinical Development of Stelara Biosimilar; Regulatory Filings Expected in Q3 MT
Formycon AG Announces Successful Results of Phase I Clinical Trial for Ustekinumab Biosimilar Candidate FYB202 and Concludes Clinical Development CI
Formycon's Interim Analysis of Late-stage Trial of Aflibercept Biosimilar Candidate Shows Efficacy Against Macular Degeneration MT
Formycon Raises EUR70 Million to Fund Biosimilar Candidates' Development MT
Formycon Licenses Stelara Biosimilar Candidate to Fresenius Unit MT
Strong Demand Prompts Formycon to Boost Size of Capital Increase MT
Formycon AG Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Chart Formycon AG
More charts
Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
46.35 EUR
Average target price
103.3 EUR
Spread / Average Target
+122.94%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Formycon AG - Xetra
  4. News Formycon AG
  5. Formycon's Eye Diseases Treatment Receives UK Marketing Authorization